BioScreen®
Clinical Services

3892 Del Amo Blvd. • Torrance, CA • 90503
(p) 310-214-0043 • (f) 310-370-3642
info@bioscreen.com • www.bioscreen.com

CLINICAL EVALUATION OF THE EFFICACY OF A SKIN CARE PRODUCT IN IMPROVING SKIN CONDITIONS

Study Number: BCS 16-057

Principal Investigator: Rania Ibrahim, Ph.D.

Sub-Investigator: Brochelle Yazzie, B.S.

Sub-Investigator: Jordan DeSantis, MHI

Sub-Investigator: Sarah Anjuwon, B.S.

Testing Facility: BioScreen Clinical Services Division
BioScreen Testing Services, Inc.
3305 N 2nd Street, Phoenix, AZ 85012
PH: 602-277-1154
FAX: 602-277-0598

Sponsor: Dermaclara
7868 Silverton Avenue, Suite B
San Diego, CA 92126

Prepared By:

_____ _____
Rania Ibrahim, Ph.D. Date

Agreed And Accepted By:

_____ _____
Dermaclara Representative Date

TABLE OF CONTENTS

RESEARCH STANDARD

The conduct of this study will comply with the International Conference of Harmonization Tripartite Guidelines on Good Clinical Practice, applicable FDA regulations/guidelines set forth in 21 CFR Parts 11 and 50 and standard practices of BioScreen.

I. OBJECTIVE

To evaluate the effectiveness of a skin care product to:

- Improve the appearance of fine lines and wrinkles in the eye area (Crow's Feet)
- Improve the appearance of fine lines and wrinkles in the forehead area
- Improve the appearance of fine lines and wrinkles in the mouth area (Nasolabial Folds)
- Improve the appearance of fine lines and wrinkles in the chest area
- Improve the appearance of stretch marks in the abdomen area

II. TESTING FACILITY

BioScreen Clinical Services Division
BioScreen Testing Services, Inc.
3305 N. 2nd Street
Phoenix, AZ 85012

III.STUDY DURATION

The study will be complete within a 1-week period.

IV.STUDY DESIGN AND METHODS

Test Product

Dermaclara Clarafuse (Silicone Pads)

Test Product Use Instructions

TBD

Test Product Handling

Test products that have been reviewed and approved for use by the Regulatory and Safety representatives of Dermaclara will be tested. A sufficient quantity of samples of the above test products to allow for 65 subjects to use for a one time application will be received from GlowBiotics prior to start of the study.

Upon arrival at BioScreen Clinical Services (BCS) the test products will be assigned a unique laboratory code number and entered into a daily log identifying the lot number, sample description, sponsor, date received and tests requested. Each individual sample of the test product will be weighed before and after use by the subject. This information will be

recorded on the test product log-in form. Samples will be retained for a period of 30 days beyond submission of final report. Sample disposition will be conducted in compliance with appropriate federal, state and local ordinances.

V. INFORMED CONSENT FORM, PHOTOGRAPHY RELEASE AND MEDICAL HISTORY FORM

An informed consent will be obtained from each volunteer prior to initiating the study describing reasons for the study, possible adverse effects, associated risks and potential benefits of the treatment and their limits of liability. Panelists will sign and date the informed consent document to indicate their authorization to proceed and acknowledge their understanding of the contents. Each subject will be assigned a permanent identification number and complete an extensive medical history and photography release form. These forms along with the signed consent forms will be available for inspection on the premises of BCS only.[1]

VI.SUBJECT SELECTION

Panel recruitment will be accomplished by advertisements in local periodicals, community bulletin boards, phone solicitation, electronic media or any combination thereof. Subject selection will be determined in accordance with the criteria listed below.

1. Number of Subjects: Approximately 65 healthy women meeting inclusion/exclusion criteria defined herein will be enrolled to complete the study with a minimum of 60 subjects
2. Sex: Female
3. Age: 45-65 years of age
4. Race: Unrestricted
5. Inclusion Criteria:
    a. Individuals in good general health.
    b. Individuals who, at baseline, are free of any dermatological or systemic disorder, which would interfere with the results, at the discretion of the Investigator.
    c. Individuals who complete a preliminary medical history.
    d. Individuals who will read, understand and sign an informed consent document.
    e. Individuals who will be able to cooperate with the Investigator and research staff, have each test product applied according to the protocol and complete the full course of the study.
    f. Individuals who have not participated in any study involving the same test site (face/chest) for 14 days prior to study start.
    g. Individuals with healthy skin on the test site, with no evidence of irritation, tattoos, scars, non-removable piercings or any other condition that would

interfere with study evaluations.

h. Individuals who will agree to refrain from using all personal care products (e.g., soaps, lotions, creams) on the test site (face/chest) 5 days prior to study start and for the entire study duration except for those products provided by BCS.
i. Individuals who agree to continue usage of their current cosmetics (e.g., foundation, blush) if applicable, so long as products contain no anti-aging properties and the subjects have a safe usage history for the duration of the study. Subjects will be instructed not to wear any form of cosmetics on the study visit days.
j. Individuals who are willing to bring their cosmetic products to the facility for inspection by a BCS staff member and agree to discontinue use of products containing anti-aging ingredients.
k. Individuals with visible fine lines and wrinkles in the eye area (Crow's feet).
l. Individuals with visible fine lines and wrinkles in the forehead area.
m. Individuals with visible fine lines and wrinkles in the mouth area (Nasolabial Folds).
n. Individuals with visible fine lines and wrinkles in the chest area.
o. Individuals who agree not to sunbathe/tan and agree to avoid sun exposure as much as possible for the duration of the study.

6. Exclusion Criteria:

a. Individuals who have had a history of any acute or chronic disease that could interfere with or increase the risk on study participation.
b. Individuals with an active (flaring) disease or chronic skin allergies (atopic dermatitis/eczema), or had recently treated skin cancer (within the last 12 months).
c. Individuals with damaged skin at or in close proximity to the test sites (e.g., sunburn, tattoos, scars or other disfigurations).
d. Individuals who have any history, which, in the Investigator's opinion, indicates the potential for harm to the subject or could place the validity of the study in jeopardy.
e. Individuals who indicate that they are pregnant, planning a pregnancy or nursing.
f. Individuals who use injectable insulin to control their diabetes.
g. Individuals who have had any medical procedure, such as laser resurfacing, or plastic surgery to the test sites within the last 12 months (including Botox, Restylyn, or other fillers).
h. Individuals who are currently using or during the last 3 months have used, Retin A, or other Rx/OTC Retinyl A, hydroquinone (skin lightening) or other astringent derived products or alpha hydroxyl acid treatments for photo-aging and fine lines/wrinkles.
i. Individuals who have a known history of hypersensitivity to any cosmetics, personal care products, fragrances and/or adhesives.

j. Individuals who are employees of BioScreen.

VII.EXPERIMENTAL TECHNIQUES

Clinical photography for Vaestro Analysis of Stretch Marks and Fine Lines, and Wrinkles in the Eye Area, Forehead Area, and Mouth Area[2-4]

Photographs are taken in accordance with regulations provided by consumer protection agencies such as the Federal Trade Commission, the Food and Drug Administration and several other regulatory authorities. The following guidelines are followed: 1) Head position is the same in before and after photos, 2) Same lighting conditions are used and the distance from the camera is same for both, before and after picture, and 3) Same room and background is used for both before and after picture.
Clinical photographs of subjects' faces (frontal, left lateral and right lateral) will be taken and evaluated with Canfield VISIA CR system using the Standard 1 modalities.

Photographs obtained will be evaluated for the appearance of fine lines and wrinkles in the eye area, forehead area, and mouth area utilizing the VAESTRO Image Analysis Toolkit.

Digital Photography for Clinical Grading Of Appearance of Fine Lines and Wrinkles in the Chest Area[2-4]

Consistency of photographic results will be achieved by eliminating all variables except the color and luminosity of the skin. Light source to subject distance will be constant for all photos. The flash units will be set so the light output is the same for every picture. The camera will be set to manual and the aperture will be determined using a light meter. The aperture and shutter speed will be held constant throughout the study. The images will not be digitally enhanced.

Digital photographs of subjects' chest (frontal) will be taken. Photographs will be analyzed for the appearance of fine lines and wrinkles on the following scale (half point increments will be used):

Overall Scale: 0=None, 1-3=Mild, 4-6 Moderate, 7-9 Severe

Self-Assessment Questionnaire

Each subject will be instructed to complete a self-assessment questionnaire provided by the Sponsor at the 1 Hour post-treatment interval.

VIII.PROCEDURE

1. Subjects will report to the facility a minimum of five (5) days prior to the start of the

study.

2. Prior to beginning any study related activities, subjects will be given an informed consent form, HIPAA form and photography release form to read.
3. Once subject has completed reading they will be interviewed, in private, by BioScreen to ensure their understanding of the aforementioned forms and be given the opportunity to ask any study related questions.
4. Subjects who agree to sign the informed consent, HIPAA and photography release forms will be asked to complete a medical history form. Subjects declining to sign the informed consent, HIPAA, or photography release form will be dismissed from the study.
5. Subjects will be enrolled on the basis of the subject selection criteria. Subjects failing to meet criteria will be dismissed from the study.
6. Enrolled subjects will begin the washout period. Subjects will receive a neutral soap (Neutrogena) to use exclusively on their face and chest during the washout period and study duration.
7. Enrolled subjects will be given specific instructions prohibiting use of all personal care products (e.g., soaps, lotions, creams) on the test sites (face and chest) for the entire washout and study duration except for those products provided by BCS.
8. Subjects will be instructed to bring their current cosmetics for inspection by a BCS staff member. Cosmetics will be inspected for anti-aging properties and safe usage history. Subject will be instructed to stop usage of any non-approved products. If subject declines, subject will be dismissed from study. Subjects will be instructed not to use any cosmetics on day of visits.
9. Following the 5 day washout period, subjects will return to the testing facility.
10. Subjects will be instructed to cleanse their face and chest with a neutral soap and gently pat dry with a paper towel.
11. Thereafter, subjects will equilibrate by remaining quietly seated for a minimum of fifteen (15) minutes in a room maintained at approximately 20-24°C and 30%-50% relative humidity. Temperature and humidity will be recorded during subject testing.
12. Following equilibration, subjects will have the below procedures/ measurements performed by trained BCS staff:

    <u>Baseline (pre-treatment)</u>

    a. Close-up facial photography
    b. Digital photography of chest

13. Subjects will instructed to use the test product as directed by the Sponsor.
14. Subjects will remain in the exam room.

15. At 1 hour (±10 minutes), Step 12 will be repeated.
16. Subjects will also be instructed to complete a post-treatment questionnaire.
17. Upon completion of the post-treatment questionnaire, subjects will be dismissed from the study and asked to participate* in a photography/videography session provided by the Sponsor.

*Subjects will only be permitted to participate in the Q&A session with the Sponsor once they have completed the study requirements as outlined in the above procedure. Participation by the subject in the photography/videography session is completely voluntary.

IX. ADVERSE EVENTS

An adverse event is any untoward medical occurrence, whether or not it is considered study related, including death, experienced by a subject. An event may consist of a disease, an exacerbation of a pre-existing illness or condition, an occurrence of an intermittent illness or condition, a set of related symptoms or signs, or a single symptom or sign.

A serious adverse event (SAE) as defined in the CFR 312.32 is "any experience that is fatal or life threatening, is permanently disabling, requires inpatient hospitalization, or is a congenital anomaly, cancer, or overdose". All serious adverse events will be reported to the sponsor within 24 hours of BCS notification.

If, according to the Investigator, medical care is warranted, appropriate referrals will be made. BCS will follow all adverse events until resolution.

X. SUBJECT DISCONTINUATION

Criteria for the discontinuation of a subject during the study will include the following:

- Significant protocol violation
- Serious adverse experience
- Request of the subject
- Any unmanageable factor, in the Investigator's opinion, that may significantly interfere with the protocol or interpretation of results.

XI.PROTOCOL AMENDMENT

Any changes to the study protocol will be approved in writing by the client and BCS prior to implementation in the study.

XII.DATA ANALYSES

Statistical analyses will test the hypothesis that the pre-treatment values of each parameter are statistically different from its post-treatment values. Statistical significance will be declared if the two-tailed p-value is ≤ 0.05.

Subject scores for each parameter in questionnaires will be presented in a tabular format. The percentage of subjects responding in favor of the test product will be reported. Statistical analysis will be performed using a z-test. Statistical significance will be declared if the p-value is ≤ 0.05.

XIII.STUDY REPORT

Final report will be issued to client within 4 weeks from study completion.

XIV.DATA ARCHIVES

All study documents, correspondence files, a copy of the final report and other source documents will be maintained on the premises of the clinic in limited-access, marked storage files. A duplicate copy of the final report will be separately archived at BioScreen Testing Laboratories, Torrance, CA.

REFERENCES

1. 21 CFR. Ch.1. Part 50, Subpart B.
2. Arch. Dermatol., 128: 347-351, 1992.
3. Br. J. Dermatol., 130: 167-173, 1994.
4. Skin Pharmacol. Appl. Skin Physiol., 16: 100-107, 2003.